Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cancer cells rely on the DNA damage response (DDR) pathway for DNA repair.
• Targeting DDR proteins with small molecules shows therapeutic potential in various cancers.
• Endometrial cancer (EC) rarely exhibits mutations in DDR genes, limiting traditional DDR inhibitor efficacy.

Purpose of the Study:

• To review the role of DNA repair in cancer development and progression.
• To discuss strategies targeting DDR proteins (PARP, CHK1, WEE1) in endometrial cancer treatment.
• To explore the combination of DDR-based therapies with immunotherapy for advanced EC.

Main Methods:

• Literature review of DDR mechanisms and therapeutic strategies in endometrial cancer.
• Analysis of preclinical and clinical data on DDR inhibitors (PARP, CHK1, WEE1) in EC.
• Summary of current immunotherapies and their potential synergy with DDR-targeted agents in advanced EC.

Main Results:

• DDR inhibitors show encouraging efficacy in preclinical and clinical models, but limited utility in EC due to rare mutations.
• Targeting DDR proteins as monotherapies or in combination with cytotoxic agents is being evaluated in EC.
• DNA damage agents can activate immune responses, suggesting potential for combining DDR inhibitors with immunotherapies.

Conclusions:

• DDR-based therapeutics, particularly in combination with immunotherapy, represent a promising future direction for advanced endometrial cancer treatment.
• Further research is needed to optimize combination strategies involving DDR inhibitors and immunomodulatory agents for EC.
• Overcoming the immune suppressive tumor environment through immune checkpoint targeting is crucial for enhancing DDR-based therapy efficacy in EC.